Fresh Options Are Emerging for Relapsed DLBCL

Christina T. Loguidice
Published: Tuesday, Apr 07, 2020
Grzegorz S. Nowakowski, MD, Associate Professor of Medicine and Oncology Mayo Clinic

Grzegorz S. Nowakowski, MD

Although considerable progress has been made in treating diffuse large B-cell lymphoma (DLBCL) since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory (R/R) disease, which is associated with considerable morbidity and mortality.1 Several treatment options exist for this patient population including high-dose therapy and transplant, as well as chimeric antigen receptor (CAR) T-cell therapy. However, as patients progress through treatments, options in subsequent lines of therapy dwindle, particularly if they are ineligible for transplant. This dilemma has led to the search for novel therapeutic approaches for patients whose disease fails to respond to currently available therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication